These clinically relevant tumor-activated γδ T cells induced strong antigen-specific CD4+ and CD8+ αβ T-cell responses and prevented immunosuppression mediated by CD4+ CD25+ Treg cells (99) (Figure 2). This evidence concerns the gene CD4 and neoplasm.